Interestingly, similar to the outcomes observed in EGFR-mutated NSCLC, the IMpower150 trial reported encouraging signals with the combination of chemotherapy, immunotherapy, and bevacizumab in ALK-rearranged tumors [93]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.